Fortunately, TetR-carrying C. trachomatis clinical strains have not yet been observed. Published data suggest that treatment failure rate during human chlamydial infections ranges from 8-23%. Multiple ...

Chlamydia is an infection caused by the bacterium Chlamydia trachomatis. It's one of the ... If you test positive for chlamydia, you can be treated very simply and quickly with oral medication.

Sanofi’s chlamydia ... treatments. Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis.

the phylogenetically distinct bacteria in phylum Chlamydiae have fascinated scientists due to their unique morphology and survival strategies. The main human pathogens among this group of obligate ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis ... can be treated with antibiotics ...

AIMS/BACKGROUND Ocular Chlamydia trachomatis infection in the west occurs as ophthalmia neonatorum, acquired from the mother, or adult paratrachoma which is also associated with current genital tract ...

The following is a summary of “Diagnostic-avoiding Chlamydia trachomatis variants detected in cervical and endometrial specimens from women during 16S microbiome profiling,” published in the March ...

Sanofi decided to begin the phase I/II study after the chlamydia vaccine candidate demonstrated promising results in pre-clinical studies. Caused by the bacterium Chlamydia trachomatis ...